Medical News on Cancer
Early Tumor Shrinkage With Cetuximab Correlates With Prolonged Survival In Metastatic Colorectal Cancer
Jun 11, 2012
Early tumor shrinkage in patients with metastatic colorectal cancer treated first line with the EGFR inhibitor cetuximab (Erbitux) is associated with prolonged survival, show results reported at the American Society of Clinical Oncology annual meeting (1-5 June 2012; Chicago, USA)... Read More
Researchers Develop And Test New Anti-Cancer Vaccine
Jun 11, 2012
Researchers at Moffitt Cancer Center have developed and tested in mice a synthetic vaccine and found it effective in killing human papillomavirus-derived cancer, a virus linked to cervical cancers among others. The research was published in a recent issue of Cancer Immunology, Immunotherapy... Read More
Genetic Mutations And Colon Cancer Development
Jun 10, 2012
In exploring the genetics of mitochondria - the powerhouse of the cell - researchers at Fred Hutchinson Cancer Research Center have stumbled upon a finding that challenges previously held beliefs about the role of mutations in cancer development. For the first time, researchers have found that the number of new mutations are significantly lower in cancers than in normal cells... Read More
Discovery Alters Traditional View Of How Prostate Cancer Develops
Jun 09, 2012
A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease... Read More
Zytiga - New Prostate Cancer Drug
Jun 08, 2012
Results from a phase III trial reveal that men with advanced prostate cancer can significantly benefit from a new medication, abiraterone acetate, called Zytiga. The researchers found that the drug maintained patients' quality of life, slowed down the spread of cancer, and delayed the development of pain and deterioration of the patients' overall condition... Read More
New Drug Shows Promise For Improved Quality Of Life In Prostate Cancer Patients
Jun 06, 2012
Men with advanced prostate cancer could significantly benefit from a new type of hormone treatment called enzalutamide (formerly MDV3100), say researchers. Results from a Phase III clinical trial showed that the enzalutamide prolonged lives of prostate cancer patients and also improved their quality of life... Read More
Advanced Prostate Cancer Patients Benefit From New Drug Zytiga
Jun 06, 2012
A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results... Read More
Immune Therapy For Cancer Ready For Wider Testing
Jun 06, 2012
Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer... Read More
Prostate Cancer Patients Fare Better On Continuous Hormone Therapy When Compared With Intermittent Hormone Therapy
Jun 05, 2012
Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a seventeen-year study led by SWOG, a cancer research cooperative group funded by the National Cancer Institute (NCI)... Read More
New Therapy On The Horizon For ALK+ Non-Small Cell Lung Cancer
Jun 05, 2012
A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib - the only approved ALK inhibitor... Read More
Previous Page Next Page